Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 547 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In-vitro Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effective Antibiotic Treatment of MRSA

NCT00388310
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Culture
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Learning From Online Video Education for Controlled Ovarian Stimulation

NCT02979990
View directory record Official record
Conditions
Self Efficacy
Interventions
Instructional Video, Control Video
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 43 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 26, 2026, 4:44 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Use of Adiana Tubal Occlusive Devices in Women With Hydrosalpinx Prior to In Vitro Fertilization

NCT01224080
View directory record Official record
Conditions
Women Suffering From Unilateral or Bilateral Tubal Occlusion Due to Hydrosalpinx
Interventions
Adiana placement
Device
Lead sponsor
Reproductive Science Center
Industry
Eligibility
21 Years to 43 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 26, 2026, 4:44 AM EDT
Terminated Not applicable Interventional

Fresh Vs Frozen Surgical Sperm in IVF

NCT03361982
View directory record Official record
Conditions
Infertility
Interventions
Slow Freezing and Thawing
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1 Interventional

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours

NCT03008018
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
KA2507
Drug
Lead sponsor
Karus Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC

NCT00000680
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 26, 2026, 4:44 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes

NCT02512796
View directory record Official record
Conditions
Gadolinium Toxicity
Interventions
Gadolinium contrast dye
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1 Interventional

BG & TMZ Therapy of Glioblastoma Multiforme

NCT01269424
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Stanton Gerson MD
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 26, 2026, 4:44 AM EDT
Terminated Not applicable Interventional

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

NCT04852029
View directory record Official record
Conditions
Infertility, Female
Interventions
Low dose hCG
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 46 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 26, 2026, 4:44 AM EDT
Withdrawn Phase 1 Interventional

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

NCT00002956
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 26, 2026, 4:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Prophylactic Antibiotics Prior to Embryo Transfer (PAPET): RCT

NCT03386227
View directory record Official record
Conditions
Assisted Reproductive Technology, Antibiotic Prophylaxis, Embryo Transfer
Interventions
Withholding antibiotic prophylaxis
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 43 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)

NCT00656201
View directory record Official record
Conditions
Infertility
Interventions
Crinone 8% Vaginal Gel, Intramuscular Progesterone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00003792
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Baylor Health Care System
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00027937
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 56 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Leuprolide acetate
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2006 · Synced Oct 26, 2026, 4:44 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

GnRH Agonist at Embryo Transfer: IVF Outcomes

NCT03544073
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male
Interventions
Saline Solution for Injection, Leuprolide Acetate
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00274846
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, in vitro treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

NCT02135302
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
eravacycline
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization

NCT00615251
View directory record Official record
Conditions
Infertility
Interventions
DR-2011, Crinone 8%
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
1,297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
29
States / cities
Tarzana, California • West Los Angeles, California • Westlake, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 26, 2026, 4:44 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Blood Collection for Development and Validation of Point-of-Care Diagnostic Liver Function Tests

NCT05457543
View directory record Official record
Conditions
Liver Diseases, Healthy, Liver Cirrhosis, Liver Fibrosis
Interventions
Adult
Diagnostic Test
Lead sponsor
Group K Diagnostics Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1 Interventional

The Effect of Acupuncture on Infertility With In-Vitro Fertilization (IVF) Patients

NCT00317317
View directory record Official record
Conditions
Infertility
Interventions
Acupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 26, 2026, 4:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions
A2B395, xT CDx with HLA-LOH assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 26, 2026, 4:44 AM EDT
Completed Phase 1Phase 2 Interventional

Senicapoc and Dehydrated Stomatocytosis

NCT04372498
View directory record Official record
Conditions
Dehydrated Hereditary Stomatocytosis
Interventions
Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 26, 2026, 4:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

NCT05845671
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 4:44 AM EDT